Ciprofol, Liver Cancer
Conditions
Keywords
Radiofreqency ablation, Liver Cancer, Ciprofol
Brief summary
Efficacy and Safety of Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation
Detailed description
Ciprofol was injected before ablation and sedation scores were measured to make sure certain sedation.
Interventions
DRUGPropofol
Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
DRUGCiprofol
Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients who intend to undergoing ultrasound-guided percutaneous radiofrequency ablation of liver tumors; * Age: 18-75 years old; * ASA grade I-III; * Laboratory examination meets the following conditions: neutrophils \>1.5×109/L, platelet \>80×109/L, hemoglobin \>90g/L, aspartate transferase \<1.5×ULN, total bilirubin \<1.5×ULN, serum creatinine \<1.2 x ULN; * Chemotherapy \< 4 times.
Exclusion criteria
* Patients who are known to be allergic to propofol, opioids, eggs, soy products, or patients who are contraindicated with these drugs or foods due to illness; * serious organ dysfunction and other systemic diseases, such as liver dysfunction, renal dysfunction; Worsening congestive heart failure within the last 6 months resulting in hospitalization or adjustment of medication; Severe aortic or mitral stenosis; Heart surgery (heart valve replacement) within the last 6 months; Acute myocardial infarction in the last 6 months; Hemodynamic disturbance due to arrhythmia; Respiratory diseases; Cerebrovascular diseases; . Taking propofol, opioids or other analgesic and sedative drugs 72 hours before . Emergency surgery; * Those who are unable to communicate with the researcher normally or who are deemed unsuitable by the researcher and refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sedation efficacy | From the start of propofol/ciprofol injection to 4 min after sedation. | Satisfaction assessed by MOAAS, Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale is a validated 6-point scale assessing responsiveness of patients coinciding with the American Society of Anesthesiologists (ASA) continuum of sedation. MOAA/S 0 to 1 represent deeper sedation, MOAA/S 2 to 3 represent moderate sedation and MOAA/S 4 to 5 represent lighter to no sedation. In this study, MOAAS between 2-3 after initial IV dosage of propofol/ciprofol was defined as efficacy sedation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory depression | From the injection of propofol/ciprofol to the period patient return to the ward, an average of 2 hours. | Any respiratory depression from the injection of propofol/ciprofol to fully recovery after surgery. Respiratory depression was defined as respiratory rate less than 10 times/min or the oxygen saturation decrease more than 5% compared with the baseline value. |
| Injection pain | From the injection of propofol/ciprofol to the end of the surgery, an average of 1 hour. | Pain during injection of propofol/ciprofol |
Countries
China
Contacts
Primary ContactXiaochun Jin, MD.
Outcome results
None listed